.png)
Sight Diagnostics
Portable machine-vision point-of-care CBC analyzer from a fingerstick (Sight OLO)
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Sight Diagnostics is positioned as a high-innovation medtech company focused on point-of-care hematology and immune-signature diagnostics, leveraging AI/computer vision to move testing away from centralized labs. Its direction appears to be broadening from CBC/fingerstick blood analysis toward a broader digital diagnostics platform with clinical and commercial expansion across multiple geographies.[15][17][1]
Efficiency Ratio
The company shows strong innovation output and credible market traction relative to a mid-sized team, but recent layoff signals indicate operational efficiency may have been under pressure despite substantial funding and product maturity.[10][5][17]
Evidence Signals
Sight OLO performs complete blood counts from finger-prick samples and is described as available across the U.S., Europe, and Asia.
The company has raised approximately $124M in funding, including a $71M Series D round reported by Business Wire coverage.
LinkedIn lists the company as privately held with 51-200 employees and 16,221 followers, indicating a meaningful but not large digital audience.
PitchBook lists Sight Diagnostics at 130 employees, suggesting a mid-sized operational footprint.
CTech reported the company laid off all of its employees, approximately 20 people, after raising $124M.
Historical reporting indicates offices in Tel Aviv, London, New York, and Jerusalem-related presence, showing international operational reach.
The company’s technology is described as AI/computer-vision-based digital microscopy that converts blood samples into analyzable images, supporting a differentiated technical platform.
- About
- Israeli AI blood-diagnostics company (HQ Tel Aviv; offices in the US and London), founded in 2011 by Yossi Pollak (CEO) and Daniel Levner. Its flagship Sight OLO is the first FDA-cleared direct-from-fingerstick point-of-care complete-blood-count (CBC) analyzer — a compact ('toaster-oven'-sized) machine-vision instrument that delivers a lab-grade 5-part differential CBC from two drops of blood in minutes, with no reagents or routine calibration. FDA 510(k)-cleared (2019), CE-marked, Health Canada and Australia POC approved; deployed with health systems (incl. Sheba during COVID) and a Pfizer partnership. Raised ~$200M over its history (Koch Disruptive Technologies, OurCrowd, CK Hutchison/Longliv, IFC). The portable, reagent-free CBC is a strong austere/field blood-diagnostics fit for C12. Note: the company has contracted sharply (from ~300 employees to ~11–50) and is repositioning toward an 'immune-intelligence' platform — a materially changed, higher-risk profile.
- Tags
- #cbc #bloodcount #pointofcare #hematology #machinevision #ai #fda #fingerstick #diagnostics